Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in RSV therapeutics.

• There will be 20,901,943 diagnosed seropositive prevalent cases of RSV across the 8MM in 2023.
• Currently, there are only three marketed drugs for RSV: two monoclonal antibodies (palivizumab and nirsevimab) and one antiviral drug (ribavirin).
• R&D activity within the RSV space is significant, with 10 pipeline products in late-stage clinical development.
• Commercial sponsors currently dominate the RSV clinical development space, with the US, Spain, and Australia emerging as key countries for conducting Phase III trials in RSV.
• Three licensing agreements, one acquisition deal, and two partnerships were implemented among companies developing RSV assets in the past 12 months.

Scope

GlobalData’s Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the RSV market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RSV market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.